Merck KGaA, Darmstadt, Germany: all 522 studies

Page 1 of 6. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasNot yet recruitingNCT07850635Phase 1
• A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy ParticipantsRecruitingNCT07840612Phase 1
• A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]Not yet recruitingNCT07840287Phase 3
• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)RecruitingNCT07549412Phase 3
• Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)RecruitingNCT07499362Phase 2
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsRecruitingNCT07360314Phase 1
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)RecruitingNCT07355218Phase 3
• A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)RecruitingNCT07340827Phase 3
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseRecruitingNCT07332481Phase 3
• Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)RecruitingNCT07176689Phase 4
• M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsRecruitingNCT07166601Phase 1
• Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibRecruitingNCT06997276Phase 1
• Anti-GD2 ADC M3554 in Advanced Solid TumorsRecruitingNCT06641908Phase 1
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Phase 3
• SW-682 in Advanced Solid TumorsRecruitingNCT06251310Phase 1
• Met Non Small Cell Cancer Registry (MOMENT)RecruitingNCT05376891
• Individual Patient Compassionate Use of NirogacestatAvailableNCT05041036
• Individual Patient Compassionate Use of MirdametinibAvailableNCT05028166
• Effect of Evobrutinib on Pharmacokinetics of a Combined Oral ContraceptiveCompletedNCT07215806Phase 1Results posted
• A TQT Study of Effect of M2951 on Cardiac RepolarizationCompletedNCT07214935Phase 1Results posted
• Relative Bioavailability of Evobrutinib Tablet BatchesCompletedNCT07214922Phase 1Results posted
• Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)TerminatedNCT06056310Phase 1Results posted
• Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)CompletedNCT05974267Phase 2Results posted
• Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)CompletedNCT05689047Phase 2Results posted
• A Study to Investigate the Association of Real-world Sensor-derived Biometric Data With Clinical Parameters and Patient-reported Outcomes for Monitoring Disease Activity in Patients With COPDCompletedNCT05655832Not applicableResults posted
• Study of M5049 in DM and PM Participants (NEPTUNIA)TerminatedNCT05650567Phase 2Results posted
• Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)CompletedNCT05650164Results posted
• Mirdametinib + BGB-3245 in Advanced Solid TumorsTerminatedNCT05580770Phase 1/2Results posted
• PK Study of Xevinapant (Debio 1143) in Healthy East Asian ParticipantsCompletedNCT05519540Phase 1Results posted
• A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has SpreadCompletedNCT05431777Results posted
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)TerminatedNCT05386550Phase 3Results posted
• A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After ChemotherapyCompletedNCT05366725Results posted
• Nirogacestat in Ovarian Granulosa Cell TumorsCompletedNCT05348356Phase 2Results posted
• A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingNCT05327530Phase 2Results posted
• DDI Study of Evobrutinib and CarbamazepineCompletedNCT05248945Phase 1Results posted
• Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)CompletedNCT05246111Phase 1Results posted
• Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy ParticipantsCompletedNCT05213481Phase 1Results posted
• Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy ParticipantsCompletedNCT05203822Phase 1Results posted
• First in Human Study of M1069 in Advanced Solid TumorsTerminatedNCT05198349Phase 1Results posted
• The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)CompletedNCT05162586Phase 2Results posted
• Drug-Drug Interaction Study of Evobrutinib and Transporter SubstratesCompletedNCT05064488Phase 1Results posted
• Bintrafusp Alfa Program Rollover StudyCompletedNCT05061823Phase 3Results posted
• Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)CompletedNCT04997148Results posted
• An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)CompletedNCT04941768Results posted
• Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)CompletedNCT04934800Results posted
• First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)CompletedNCT04882917Phase 1Results posted
• Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)CompletedNCT04783935Phase 4Results posted
• Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)CompletedNCT04776213Phase 4Results posted
• Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)CompletedNCT04768296Phase 2Results posted
• GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) StudyCompletedNCT04684420Phase 1Results posted
• Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)CompletedNCT04551950Phase 1Results posted
• Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PKCompletedNCT04546789Phase 1Results posted
• Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)TerminatedNCT04515394Phase 2Results posted
• Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast CancerTerminatedNCT04489940Phase 2Results posted
• A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)TerminatedNCT04459715Phase 3Results posted
• First in Human Study of M6223CompletedNCT04457778Phase 1Results posted
• Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)CompletedNCT04448756Phase 2Results posted
• Study of Evobrutinib in Participants With RMS (evolutionRMS 2)TerminatedNCT04338061Phase 3Results posted
• Study of Evobrutinib in Participants With RMS (evolutionRMS 1)TerminatedNCT04338022Phase 3Results posted
• Bioequivalence Study of Coated Cesol Tablet Formulation Versus BiltricideCompletedNCT04314037Phase 1Results posted
• Chemoprophylactic Activity of M5717 in PfSPZ Challenge ModelCompletedNCT04250363Phase 1Results posted
• Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical CancerCompletedNCT04246489Phase 2Results posted
• Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of TepotinibCompletedNCT04204902Phase 1Results posted
• First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With DexamethasoneTerminatedNCT04075721Phase 1Results posted
• Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTCTerminatedNCT04066491Phase 2/3Results posted
• Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet FormCompletedNCT04037748Phase 1Results posted
• Study of Evobrutinib in Participants With RMSTerminatedNCT04032171Phase 3Results posted
• Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)TerminatedNCT04032158Phase 3Results posted
• A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy VolunteersCompletedNCT03979274Phase 1Results posted
• MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive, not recruitingNCT03962543Phase 2Results posted
• Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)CompletedNCT03961204Phase 4Results posted
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedNCT03940703Phase 2Results posted
• A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)CompletedNCT03933215Results posted
• A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)CompletedNCT03933202Results posted
• Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)TerminatedNCT03858049Phase 4Results posted
• L-PZQ ODT in Schistosoma Infected ChildrenCompletedNCT03845140Phase 3Results posted
• M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT03840915Phase 1/2Results posted
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)TerminatedNCT03840902Phase 2Results posted
• M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)CompletedNCT03833661Phase 2Results posted
• Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)CompletedNCT03785964Phase 3Results posted
• Study of Peposertib in Combination With Capecitabine and RT in Rectal CancerCompletedNCT03770689Phase 1/2Results posted
• Effects of Cladribine Tablets on the PK of Microgynon®CompletedNCT03745144Phase 1Results posted
• Study of Avelumab-M3814 CombinationsCompletedNCT03724890Phase 1Results posted
• Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLCCompletedNCT03717155Phase 2Results posted
• Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian CancerCompletedNCT03704467Phase 1Results posted
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03631706Phase 3Results posted
• Bioequivalence of TF3 and TF2 and Effect of Food on the PK of TepotinibCompletedNCT03629223Phase 1Results posted
• Effect of Tepotinib on PK of CYP3A Substrate MidazolamCompletedNCT03628339Phase 1Results posted
• Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) StudyCompletedNCT03583385Phase 1Results posted
• Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)CompletedNCT03566810Phase 1Results posted
• Tepotinib Hepatic Impairment TrialCompletedNCT03546608Phase 1Results posted
• Effect of a Proton Pump Inhibitor on the PK of TepotinibCompletedNCT03531762Phase 1Results posted
• Phase I/Ib Multiple Ascending Dose Study in ChinaCompletedNCT03523390Phase 1Results posted
• Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran EtexilateCompletedNCT03492437Phase 1Results posted
• A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy ParticipantsCompletedNCT03467971Phase 1Results posted
• Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy ParticipantsCompletedNCT03467945Phase 1Results posted
• Phase I/II Study of Avelumab in Pediatric Cancer ParticipantsTerminatedNCT03451825Phase 1Results posted
• Praziquantel Bioequivalence StudyCompletedNCT03437447Phase 1Results posted
• Glucophage Immediate Release (GIR) China Bioequivalence StudyCompletedNCT03393208Phase 1Results posted
• Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice ForielleTerminatedNCT03387059Phase 4Results posted

← Merck KGaA, Darmstadt, Germany overview and focus areas